SCHEMBL29909220

SCHEMBL29909220

COc1ccc(-c2cccc(N(C)c3nc4nncn4c4cc([N+](=O)[O-])ccc34)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 3/20 0.43
▸ PLAU P00749 2/20 0.41
▸ NPC1 O15118 5/20 0.39
▸ RAB9A P51151 5/20 0.39
▸ MAPT P10636 5/20 0.39
▸ SMN1; SMN2 Q16637 5/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ GAA P10253 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ STAT1 P42224 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPBWR1 P48145 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ SAE1 Q9UBE0 1/20 0.39
▸ UBA2 Q9UBT2 1/20 0.39
▸ PLG P00747 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23577259 1.00 ABCG2 (0.43) ABCG2PLAUNPC1RAB9AMAPT
SCHEMBL23576737 0.91 ABCG2 (0.52) ABCG2MAPTLMNAHTTNPBWR1
SCHEMBL29909184 0.91 ABCG2 (0.52) ABCG2MAPTLMNAHTTNPBWR1
SCHEMBL23578021 0.90 ABCG2 (0.45) ABCG2NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL29909003 0.90 ABCG2 (0.45) ABCG2NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL23576891 0.90 ABCG2 (0.44) ABCG2SMN1; SMN2ALDH1A1
SCHEMBL29909490 0.90 ABCG2 (0.44) ABCG2SMN1; SMN2ALDH1A1
SCHEMBL24721227 0.86 TP53 (0.41) MAPTKMT2AALDH1A1
SCHEMBL29909355 0.85 ABCG2 (0.41) ABCG2PLAUMAPTSMN1; SMN2MEN1
SCHEMBL23600785 0.85 TP53 (0.37) MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK ABCG2 4216/4885PLAU 3029/4885NPC1 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback